Eisai Co. Ltd announced that the company will present new data from the phase 3 Clarity AD study for its Alzheimer’s disease treatment LEQEMBI® 100 mg/mL injection for intravenous use and new data on the subcutaneous formulation in development at the 16th annual Clinical Trials on Alzheimer’s Disease conference.
